Literature DB >> 30480858

Buprenorphine: Therapeutic potential beyond substance abuse.

Stephani Velasquez1, Jay Rappaport2.   

Abstract

Discussion of buprenorphine and its potential utility for the treatment of inflammatory disorders. ©2018 Society for Leukocyte Biology.

Entities:  

Keywords:  immune activation; inflammation; monocyte; opioids; transmigration

Mesh：

Substances：

Year:  2018        PMID： 30480858      PMCID： PMC6476568          DOI： 10.1002/JLB.3CE0418-172R

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN： 0741-5400            Impact factor:   4.962


  10 in total

1.  Pivotal function for cytoplasmic protein FROUNT in CCR2-mediated monocyte chemotaxis.

Authors:  Yuya Terashima; Nobuyuki Onai; Masako Murai; Masahiko Enomoto; Vongsakorn Poonpiriya; Tsuyoshi Hamada; Kazushi Motomura; Makiko Suwa; Taichi Ezaki; Tatsuya Haga; Shiro Kanegasaki; Kouji Matsushima
Journal:  Nat Immunol       Date:  2005-07-03       Impact factor: 25.606

2.  Altered neuro-inflammatory gene expression in hippocampus in major depressive disorder.

Authors:  Gouri J Mahajan; Eric J Vallender; Michael R Garrett; Lavanya Challagundla; James C Overholser; George Jurjus; Lesa Dieter; Maryam Syed; Damian G Romero; Hamed Benghuzzi; Craig A Stockmeier
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2017-11-22       Impact factor: 5.067

3.  Buprenorphine differentially affects M1- and M2-polarized macrophages from human umbilical cord blood.

Authors:  Juan Sun; Wei Guo; Xingguang Du
Journal:  Eur Cytokine Netw       Date:  2017-06-01       Impact factor: 2.737

4.  Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes.

Authors:  Elaine Setiawan; Alan A Wilson; Romina Mizrahi; Pablo M Rusjan; Laura Miler; Grazyna Rajkowska; Ivonne Suridjan; James L Kennedy; P Vivien Rekkas; Sylvain Houle; Jeffrey H Meyer
Journal:  JAMA Psychiatry       Date:  2015-03       Impact factor: 21.596

5.  Buprenorphine Maintenance Subjects Are Hyperalgesic and Have No Antinociceptive Response to a Very High Morphine Dose.

Authors:  Peter Athanasos; Walter Ling; Felix Bochner; Jason M White; Andrew A Somogyi
Journal:  Pain Med       Date:  2019-01-01       Impact factor: 3.750

6.  Possible antidepressive effects of opioids: action of buprenorphine.

Authors:  H M Emrich; P Vogt; A Herz
Journal:  Ann N Y Acad Sci       Date:  1982       Impact factor: 5.691

7.  Buprenorphine decreases the CCL2-mediated chemotactic response of monocytes.

Authors:  Loreto Carvallo; Lillie Lopez; Fa-Yun Che; Jihyeon Lim; Eliseo A Eugenin; Dionna W Williams; Edward Nieves; Tina M Calderon; Carlos Madrid-Aliste; Andras Fiser; Louis Weiss; Ruth Hogue Angeletti; Joan W Berman
Journal:  J Immunol       Date:  2015-02-25       Impact factor: 5.422

8.  Preliminary assessment of a 10-day rapid detoxification programme using high dosage buprenorphine.

Authors:  J Vignau
Journal:  Eur Addict Res       Date:  1998       Impact factor: 3.015

9.  Altered KYN/TRP, Gln/Glu, and Met/methionine sulfoxide ratios in the blood plasma of medication-free patients with major depressive disorder.

Authors:  Hidehiro Umehara; Shusuke Numata; Shin-Ya Watanabe; Yutaka Hatakeyama; Makoto Kinoshita; Yukiko Tomioka; Kiyoshi Nakahara; Takeshi Nikawa; Tetsuro Ohmori
Journal:  Sci Rep       Date:  2017-07-07       Impact factor: 4.379

Review 10.  Neuropathology of mood disorders: do we see the stigmata of inflammation?

Authors:  N Mechawar; J Savitz
Journal:  Transl Psychiatry       Date:  2016-11-08       Impact factor: 6.222
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.